^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Microbiome modulator

    Related drugs:
    Apply
    Pembrolizumab and EDP1503 in Advanced Melanoma (NCT03595683)
    Phase 2
    University of Chicago
    Active, not recruiting
    Last update posted :
    07/31/2024
    Initiation :
    10/02/2018
    Primary completion :
    11/02/2027
    Completion :
    11/02/2027
    BRAF
    |
    Keytruda (pembrolizumab) • EDP1503
    Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy (MET4-IO) (NCT03686202)
    Phase 2/3
    University Health Network, Toronto
    Active, not recruiting
    Last update posted :
    03/15/2024
    Initiation :
    11/30/2018
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    BRAF
    CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant (NCT03922035)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/22/2024
    Initiation :
    04/18/2019
    Primary completion :
    12/24/2024
    Completion :
    12/24/2024
    TNFA • TNFRSF1A • TGFB1
    |
    Cdactin-O (CBM588)
    CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer (P30CA033572) (NCT03829111)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/01/2024
    Initiation :
    05/14/2019
    Primary completion :
    06/11/2024
    Completion :
    06/11/2024
    IL6 • CXCL8
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cdactin-O (CBM588)
    Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer (NCT05877430)
    Phase 1/2
    CJ Bioscience, Inc.
    Recruiting
    Last update posted :
    12/18/2023
    Initiation :
    09/11/2023
    Primary completion :
    07/01/2026
    Completion :
    10/01/2027
    BRAF
    |
    PD-L1 expression • BRAF mutation • BRAF V600
    |
    Keytruda (pembrolizumab) • CJRB-101
    Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer (NCT05462496)
    Phase 2
    Icahn School of Medicine at Mount Sinai
    Recruiting
    Last update posted :
    11/18/2023
    Initiation :
    03/13/2023
    Primary completion :
    12/01/2024
    Completion :
    07/01/2025
    CD38 • IL2RA • CD69 • ISG20
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma (PICASSO) (NCT04988841)
    Phase 2
    Assistance Publique - Hôpitaux de Paris
    Recruiting
    Last update posted :
    09/26/2023
    Initiation :
    01/20/2022
    Primary completion :
    01/20/2024
    Completion :
    06/01/2024
    IL6 • ISG20
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • MaaT013
    PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN) (NCT05743777)
    Phase 2
    Canadian Cancer Trials Group
    Withdrawn
    Last update posted :
    05/18/2023
    Initiation :
    05/12/2023
    Primary completion :
    05/12/2023
    Completion :
    05/12/2023
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)